New antibiotic cocktail aims to beat infections in cancer patients

NCT ID NCT04983901

Completed Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tested whether a newer antibiotic combination (imipenem-relebactam) works better than standard antibiotics for treating fever caused by low white blood cell counts in cancer patients. About 100 adults with cancer or who had a stem cell transplant took part. The study compared how well each treatment controlled the infection during their hospital stay.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Imipenem-relebactam (antibiotic combination)
What this could lead to: If successful, this could offer a more effective antibiotic option for cancer patients with fever and low white blood cell counts, potentially reducing treatment failures.
What could go wrong: This is a small, early-phase trial (100 participants) at a single center. Results may not apply broadly, and the drug may not outperform current standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM MALIGNANT SOLID NEOPLASM

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.